Embecta reports Q1 adjusted EPS 71c, consensus 67c

Reports Q1 revenue $261.2M, consensus $258.07M. “During the first quarter our results were largely consistent with our expectations,” said Devdatt Kurdikar, CEO. “As we look ahead, we remain focused on pursuing initiatives that will transform the company into a broadbased medical supplies company which serves chronic care patients and drug delivery partners. This includes maintaining our global leadership position in core injection products, expanding our product portfolio, and creating additional financial flexibility through ongoing debt reduction. Given our performance during the first quarter, coupled with our outlook for the remainder of the year, we are maintaining our previously provided guidance for key financial reporting metrics”.